project id: TCGA-BLCA; case submitter id: TCGA-DK-A6AV; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.89; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.78; rna integrity number: 7.0; age at index: 82; days to birth: -30089; ethnicity: not hispanic or latino; gender: female; race: asian; vital status: Alive; year of birth: 1926; age at diagnosis: 30089; ajcc clinical t: T2; ajcc pathologic m: M0; ajcc pathologic n: N0; ajcc pathologic stage: Stage II; ajcc pathologic t: T2a; ajcc staging system edition: 6th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 1952.0; icd 10 code: C67.1; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Dome of bladder; synchronous malignancy: No; tissue or organ of origin: Dome of bladder; tumor grade: Not Reported; year of diagnosis: 2008; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 0.6575342465753424; pack years smoked: 12.0; is ffpe: false; weight: 30.0; composition: Not Reported; days to collection: 1836; days to sample procurement: 0; initial weight: 80.0; portion submitter id: TCGA-DK-A6AV-01A-12; percent lymphocyte infiltration: 10.0; percent monocyte infiltration: 0.0; percent necrosis: 4.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 30.0; percent tumor cells: 66.0; percent tumor nuclei: 85.0;